Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

医学 内科学 细胞因子释放综合征 回顾性队列研究 免疫疗法 癌症 嵌合抗原受体
作者
Amneet Bajwa,Qiuhong Zhao,Marcus Geer,Agrima Mian,Chenyu Lin,David Frame,James Westholder,Justin Tossey,Monalisa Ghosh,Ahmed Galal,Nausheen Ahmed,Joseph Maakaron,Nathan Denlinger,Marcos de Lima,Narendranath Epperla,Paolo F. Caimi,Timothy Voorhees
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4502-4502 被引量:8
标识
DOI:10.1182/blood-2023-179620
摘要

Background: Chimeric Antigen Receptor T-Cell therapies (CAR-T) are effective in a variety of hematologic (hem) malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can affect a significant number of patients (pts). Tocilizumab, a monoclonal antibody (mAb) binding the interleukin-6 (IL-6) receptor, is the standard of care for managing CRS, but is ineffective for ICANS. Corticosteroids remain the standard of care for managing ICANS. Pts who develop refractory CRS or ICANS have few treatment options. Siltuximab, a mAb binding circulating IL-6, has been proposed to have clinical activity in both CRS and ICANS (Patel, ASH, 2022; Narkhede, TCT, 2023). This study assesses the efficacy of siltuximab for managing CRS and ICANS in a real-world cohort from six academic medical centers. Methods: We conducted a multicenter retrospective review of adult pts with hem malignancies treated with CAR-T therapy who received siltuximab for treatment of CRS and/or ICANS. Siltuximab administration occurred between January 2020 and August 2022. Pts who died within 48 hours of siltuximab administration (n=2) were excluded from this analysis. The co-primary endpoints were the percentage of pts who had improvement in CRS or ICANS after receiving siltuximab. Secondary endpoints included time to improvement of CRS or ICANS and overall survival (OS) from the date of CAR-T infusion. Time to event endpoints were evaluated by Kaplan-Meier methodology. Results: Fifty-two pts were eligible and evaluated. The median age was 60 years (range 23-81). Diffuse large B-cell lymphoma was the most common hem malignancy (52%). Axicabtagene ciloleucel (42%) was the most common cellular therapy product. Table 1 describes disease subtypes and cell therapy products in detail. Fifty-one pts (98%) developed CRS with median time to onset of 2 days (range 0-9). Max CRS grade prior to siltuximab administration was grade 1-2 in 83% and grade 3-4 in 15%. ICANS occurred in 65% with median time to onset of 6 days (range 0-16). Max ICANS grade prior to siltuximab administration was grade 1-2 in 29% and grade 3-4 in 37%. Prior to siltuximab, 52% of pts received tocilizumab with the majority (59%) receiving more than 1 dose, 69% of pts received corticosteroids, and 10 pts received additional treatments: anakinra (7/10 pts), LP with intrathecal (IT) chemo (3/10 pts), LP with IT steroids (2/10 pts), ruxolitinib (1/10 pt). Reasons for siltuximab administration included steroid refractory ICANS in 17 pts (33%), tocilizumab refractory CRS in 8 pts (15%), tocilizumab shortage in 26 pts (50%), and non-steroid refractory grade 4 ICANS in 1 pt (2%). At the time of siltuximab administration, 42 pts (81%) had evidence of CRS (10% grade 3-4 CRS) and 28 pts (54%) had evidence of ICANS (31% grade 3-4 ICANS). 18 pts (35%) had concurrent CRS and ICANS. Thirty-six pts (86%) had improved CRS grade following siltuximab treatment. The median time to CRS resolution after siltuximab was 1.5 days (range 0-18). Twelve pts with CRS received more than 1 dose of siltuximab. 4/8 pts (50%) with tocilizumab refractory CRS had improved CRS grade after siltuximab. Nineteen pts (68%) had improved ICANS grade following siltuximab treatment. The median time to ICANS resolution after siltuximab was 5 days (range 1-40). Nine pts with ICANS received more than 1 dose of siltuximab. 13/17 pts (76%) with steroid refractory ICANS had improved ICANS grade after siltuximab. The median time to discharge after siltuximab administration was 14 days (range 7-90). CAR-T therapy objective response rate was 73% and complete response rate was 48%. Twenty-one pts had died at the time of data collection; 4 deaths were deemed secondary to CAR-T toxicity. The median OS was 13.8 months (95% CI 9.6-NR) and was not statistically different based on indication of CAR-T therapy, Figure 1. Conclusions: To our knowledge, this is the largest cohort of pts treated with siltuximab for CRS and/or ICANS following CAR-T therapy. Half of the pts had CRS or ICANS refractory to tocilizumab and/or steroids. Siltuximab appeared to be effective for both CRS and ICANS, including refractory toxicities. These data support the use of siltuximab for refractory CRS and ICANS and warrant further investigation of siltuximab in earlier lines of therapy for CRS and ICANS management.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
rongliy完成签到,获得积分10
刚刚
chole发布了新的文献求助10
1秒前
yi发布了新的文献求助10
1秒前
1秒前
1秒前
1717发布了新的文献求助10
2秒前
脱羰甲酸发布了新的文献求助10
2秒前
方青松发布了新的文献求助10
2秒前
雪落发布了新的文献求助10
2秒前
Ava的应助被乐观的大树采纳,获得10
2秒前
2秒前
4秒前
Hello的应助被steplight采纳,获得10
4秒前
方方土发布了新的文献求助10
4秒前
蓝天的应助被steplight采纳,获得10
4秒前
万能图书馆的应助被steplight采纳,获得10
4秒前
星辰大海的应助被steplight采纳,获得10
4秒前
小二郎的应助被steplight采纳,获得10
4秒前
蓝天的应助被steplight采纳,获得10
4秒前
所所的应助被steplight采纳,获得10
4秒前
细心鲂完成签到,获得积分20
4秒前
赘婿的应助被steplight采纳,获得10
5秒前
思源的应助被steplight采纳,获得10
5秒前
科研通AI65的应助被陈陌与采纳,获得10
5秒前
肥龙宝宝发布了新的文献求助10
6秒前
dit发布了新的文献求助10
7秒前
嘻嘻哈哈的应助被lifarshad采纳,获得10
7秒前
加点辣椒面吧完成签到,获得积分10
7秒前
斯文败类的应助被DW采纳,获得10
9秒前
10秒前
夜绿完成签到,获得积分10
10秒前
11秒前
Adzuki0812完成签到,获得积分10
11秒前
斯文败类的应助被肥龙宝宝采纳,获得10
14秒前
14秒前
闪闪映天完成签到 ,获得积分10
14秒前
强健的碧琴完成签到,获得积分10
15秒前
隐形的凡阳完成签到,获得积分10
15秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188353
求助须知:如何正确求助?哪些是违规求助? 9576169
关于积分的说明 21845860
捐赠科研通 7786410
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482235